tbuckley/cabot-search huggingface dataset:
Supportive Psychotherapy
Authors: Hellmuth Freyberger, Harald-J. Freyberger
Journal: Psychotherapy and Psychosomatics (1994)

By way of introduction the concepts 'helpful-supportive' (in analytical psychotherapy) and 'exclusive-supportive' psychotherapy are defined. Then the indications and the patients' characteristics (marked ego weakness, dependency wishes) concerning exclusive-supportive psychotherapy in psychosomatic medicine are outlined. After this we describe the three interview and treatment steps of supportive psychotherapy in psychosomatic patients which particularly include the patients' motivation for conflict-enlightenment psychotherapy. Furthermore some effectiveness criteria are presented. Apart from this motivation work, there exists an indication for supportive long-term psychotherapy in psychosomatic patients. Exclusive-supportive psychotherapy in chronically medically ill patients is founded upon the instability of the psychic adaptation processes (particularly the labilized denial work) following the manifestation of chronic disease. The characteristic intervention techniques deal with the patient's secondary frustration-aggression following, on the one hand, his idea 'Why am I so ill and not the others'. On the other hand, supportive-psychotherapeutic handling of the patient's acute or long-lasting conflict situations prevails. Additional systemic psychotherapeutic procedures are highly recommended in psychosomatic and chronically ill patients, for these procedures are well suited to promoting the effectiveness of individual supportive psychotherapy.
HIV Infection and Smoking Behavior
Authors: Jonathan M. Samet
Journal: JAMA (1992)

<h3>To the Editor.</h3> —The interesting study by Halsey et al<sup>1</sup>showed an association between smoking and an increased risk of human immunodeficiency virus type 1 (HIV-1) infection in Haitian women. We would like to add a few comments to the authors' discussion of their findings. The authors investigated the risk of HIV infection among "women who reported during the first interview that they had ever smoked." Presumably, every smoker in this case included current and former smokers. The authors did not report the percentage of ever smokers in their study who were former smokers. The observation that 29 (33%) of the 89 smokers at the first interview had stopped smoking by the second interview implies that a substantial proportion of the smokers at the first interview may have been former smokers. If the risk of HIV infection declines after smoking cessation—as do the risks of most smoking-related diseases<sup>2</sup>—the
Surgeon's Story
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Public Health and Ethnicity
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE SPLEEN IN MEASLES—AN OVERLOOKED SYMPTOM
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Second Thoughts on Primary Disease
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SIR VICTOR HORSLEY (1857-1916-NEUROSURGEON
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0111 Membrane tnf expression on monocytes and differentiation of monocytes into m2-m1 macrophages: 2 new biomarkers of rheumatoid arthritis
Authors: A. Paoletti, G. Nocturne, S. Bitoun, E. Riviere, J. Pascaud, B. Ly, X. Mariette
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Three monocyte subsets have been described based on their CD14 and CD16 expression profiles, the subpopulation CD14<sup>+</sup>CD16<sup>+</sup> being expanded in rheumatoid arthritis (RA) patients. Macrophages contribute <i>in situ</i> to the RA pathogenesis. They can display various states of activation or « polarisation ». Two distinct states of polarisation for macrophages have been recognised: the <b>"classically activated macrophage phenotype"</b> (M1) and the <b>"alternatively activated macrophage phenotype"</b> (M2). To sum-up, M1 are considered to be pro-inflammatory and M2 to be regulatory and anti-inflammatory. <h3>Objectives</h3> Here, we have assessed monocytes subsets and their capacity of differentiation into M2 or M1 macrophages in RA patients and controls. <h3>Methods</h3> PBMCs were isolated and we first determined monocytes subpopulations and looked at expression of membrane TNF (mTNF). After negative selection of monocytes, Macrophages were Derived from Monocytes(MDM) by 7 days of culture in the presence of M-CSF (M2 differentiation) or GM-CSF (M1 differentiation). Expression of total macrophages markers (CD11b and CD71) and the M2 macrophage polarisation markers (CD163 and CD206) were evaluated. <h3>Results</h3> We have confirmed that the CD14<sup>+</sup>CD16<sup>+</sup>monocytes subset was expanded in RA patients. For the first time, we have demonstrated that mTNF expression was significantly increased only in monocytes in RA patients (CD14<sup>+</sup>: Mean <b>5.6%</b> HD versus <b>10.6%</b> RA, CD14<sup>+</sup>CD16<sup>+</sup>: Mean <b>3.3%</b> HD versus <b>11.1%</b> RA, CD16<sup>+</sup>: Mean <b>2.4%</b> HD versus <b>6.3%</b> RA). Moreover, mTNF expression on monocytes correlated with the activity of the disease assessed by DAS28 CRP (Spearman r <b>0.548</b> and <b>p=0.0021*</b>). We have observed a significant decrease of macrophages induction by M-CSF in RA patients as shown by a decreased expression of CD11b-CD71(Mean <b>87.2%</b> HD versus <b>57.1%</b> RA, <b>P value ****</b>). Among MDM, we have found a specific decreased level of M2 markers (CD206 Mean <b>78.1%</b> HD versus <b>27%</b> RA and CD163 <b>56.2%</b> HD versus <b>37.2%</b> RA) suggesting an impaired maturation to M2 stage in RA patients. <h3>Conclusions</h3> Monocytes from RA patients have an increased expression of mTNF linked to activity of the diseases. RA patients have an impaired maturation of monocytes to M2 macrophages. This might suggest that RA monocytes have a propensity for preferential maturation towards a pro-inflammatory M1 phenotype thus contributing to synovial inflammation. Deeper characterisation of M1/M2 and effect of the different types of anti-TNF on this differentiation process are on-going and will be presented. <h3>Disclosure of Interest</h3> None declared
Risks for Bleeding in Patients with Pulmonary Embolism Treated with Thrombolytic Agents
Authors: Chris Hogness
Journal: Annals of Internal Medicine (1995)

Letters15 April 1995Risks for Bleeding in Patients with Pulmonary Embolism Treated with Thrombolytic AgentsChris HognessChris HognessSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-8-199504150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Stein and colleagues [1] used data on myocardial infarction to make an important statistical argument that bleeding caused by thrombolytic agents that were given for noninvasively diagnosed pulmonary embolism would be less than the bleeding after a diagnosis established by an invasive (angiographic) procedure. However, they do not adequately discuss the potential problems of comparing apples with oranges.The risk ratio for bleeding events when invasive compared with noninvasive methods are used after myocardial infarction might be different than the same ratio after pulmonary embolism. Venous pressures may be higher after a massive pulmonary embolus, which could ...REFERENCE1. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med. 1994; 121:313-7. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1995Volume 122, Issue 8Page: 630-632KeywordsCannulationHemorrhageMyocardial infarctionPulmonary embolismRisk ratioStatistical dataSurgeryVeins ePublished: 15 August 2000 Issue Published: 15 April 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
PROSPECTUS
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aflibercept
Authors: Kristen K. Ciombor, Jordan Berlin, Emily Chan
Journal: Clinical Cancer Research (2013)

Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen. In the phase III VELOUR trial, aflibercept plus FOLFIRI statistically significantly prolonged both progression-free survival (PFS; median PFS for the aflibercept plus FOLFIRI arm was 6.90 vs. 4.67 months for the placebo-plus-FOLFIRI arm) and overall survival (median overall survival for the aflibercept-plus-FOLFIRI arm was 13.50 vs. 12.06 months for the placebo plus FOLFIRI arm), but grade 3 or 4 adverse events were more common with the addition of aflibercept. However, the addition of aflibercept to 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in the phase II AFFIRM trial of first-line treatment of mCRC failed to improve PFS or response rate. As a decoy VEGF receptor, aflibercept (VEGF-Trap) has binding affinity for VEGF-A, VEGF-B, PlGF-1, and PlGF-2, and this is a mechanism of significant interest. Optimal strategies for incorporating aflibercept into treatment regimens that include other anti-VEGF and cytotoxic chemotherapeutic agents, as well as development of predictive biomarkers for treatment response, have yet to be defined.
Reply: Prostate Cancer
Journal: JNCI Journal of the National Cancer Institute (1986)

Reply: Prostate Cancer Get access Hari H. Dayal, Hari H. Dayal Fox Chase Cancer Center, 430(B) Rhawn Street, Philadelphia, Pennsylvania 19111 Search for other works by this author on: Oxford Academic PubMed Google Scholar Lincoln Polissar, Lincoln Polissar Fred Hutchinson Cancer, Research Center, 1124 Columbia Street, Seattle, Washington 98104 Search for other works by this author on: Oxford Academic PubMed Google Scholar Steven Dahlberg Steven Dahlberg Fred Hutchinson Cancer, Research Center, 1124 Columbia Street, Seattle, Washington 98104 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Pages 1259–1260, https://doi.org/10.1093/jnci/76.6.1259-a Published: 01 June 1986
Diathermy in the Treatment of Genito-Urinary Diseases, with Especial Reference to Cancer.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentary
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brain Abscess
Authors: M. Ellis
Journal: BMJ (1955)

107 patients with neonatal tetanus were studied and the value of intrathecal antitetanus serum with steroid was noted. The mortality rate in a control group (68%) was significantly higher than that of the test group (37%). Furthermore, a delay in antitetanus serum administration was found to have a strong positive linear correlation with the mortality rate. In fact, the mortality rate for neonates who were given antitetanus serum 24 hours after the onset of convulsions was found to be as high as for the control group. This suggests that intrathecal antitetanus serum is ineffective unless it is administered within 24 hours of the onset of convulsions. There was no significant difference in mortality rate whether a dose of 100 units or one of 50 units antitetanus serum was given intrathecally. The mean duration in hospital for survivals of the test group (7.4 days) was significantly shorter than that for survivals of the control group (10.4 days). No complication of intrathecal antitetanus serum was observed during the study.
“Focus on…” Session: allogeneic transplantation
Authors: A Sureda, M Zang, P Hari, S Montoto, G Laport, H Lazarus, M Attal, N Russell, K Thompson, J Vernant, C Canals, P Dreger, H Schouten, M Pasquini, D Maloney, J Carreras, M Zhang, T Fenske, S Robinson, J Luan, K Peggs, S Le Gouill, K Nicolaus, N Milpied, J Jouet, J Briones, F Guilhot, J Finke, N Schmitz, B Glass, J Hasenkamp, W Jung, C Wilhelm, G Held, M Nickelsen, M Pfreundschuh, L Tru ¨mper, G Wulf
Journal: Annals of Oncology (2011)
Two-Part Symposium on Lipids Planned
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal